Adjuvant chemotherapy for colon cancer in the elderly: Moving from evidence to practice

ONCOLOGY

Volumn 23, Issue 2, 2009, Pages 162-167

  Ades, Steven ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; OXALIPLATIN;

ADJUVANT THERAPY; AGE; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER REGRESSION; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; COMORBIDITY; DAILY LIFE ACTIVITY; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG SAFETY; ELDERLY CARE; EVIDENCE BASED PRACTICE; FATIGUE; FINANCIAL MANAGEMENT; FRAIL ELDERLY; HUMAN; INDIVIDUALIZATION; LIFE TABLE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICARE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT SELECTION; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RECURRENCE RISK; SOCIAL SUPPORT; THROMBOEMBOLISM; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; NEOPLASM STAGING; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 63249127366     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. US Census Bureau: U.S. interim projections by age, sex, race, and Hispanic origin: 200-2050. Available at www.census.gov. Accessed Jan 18, 2009. Internet-release date: March 18, 2004.
2. Heron MP, Hoyert DL, Xu J, et al: Deaths: Preliminary data for 2006, in National Vital Statistics Reports: Center for Disease Control & Prevention, pp 1-52, 2008.
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
4. Yancik R, Ries LA: Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14:17-23, 2000.
5. NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990.
6. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Colon cancer, version 4.2008. Available at www.nccn.org. Accessed Jan 18, 2009.
7. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447-1456,1989.
8. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990.
9. Kahn KL, Adams EE, Chrischilles DP, et al: Are we use of chemotherapy for elderly stage III colon cancer patients? An analysis from the Cancer Care Outcomes & Research Surveillance Consortium (CanCORS) (abstract 6500). J Clin Oncol 26(15S):337s, 2008.
10. Mahoney T, Kuo YH, Topilow A, et al: Stage III colon cancers: Why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 135:182-185, 2000.
11. Potosky AL, Harlan LC, Kaplan RS, et al: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192-1202, 2002.
12. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage HI colon cancer. J Natl Cancer Inst 93:850-857, 2001.
13. Davidoff AJ, Choti MA, Zuckerman IH, et al: Is there evidence of diminishing disparities in treatment (tx) with adjuvant (adj) chemotherapy (Ch) among elderly (E) stage 3 colon cancer (CC) patients (pts)? An analysis of 8,374 pts from SEER-Medicare data (abstract 6574). J Clin Oncol 26(15S):355s, 2008.
14. Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 294:2703-2711, 2005.
15. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001.
16. Hutchins LF, Unger JM, Crowley JJ, et al: Under-representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999.
17. Sateren WB, Trimble EL, Abrams J, et al: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109-2117, 2002.
18. Lewis JH, Kilgore ML, Goldman DP, et al: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389, 2003.
19. Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136:349-357, 2002.
20. Iwashyna TJ, Lamont EB: Effectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage In colon cancer. J Clin Oncol 20: 3992-3998, 2002.
21. Zuckerman IH, Davidoff AJ, Onukwugha E, et al: Effect of age on survival benefit of adjuvant chemotherapy in elderly stage III colon cancer patients: A population-based analysis (abstract 4014). J Clin Oncol 26(15S):181s, 2008.
22. Dobie SA, Baldwin LM, Dominitz JA, et al: Completion of therapy by Medicare patients with stage 1/I colon cancer. J Natl Cancer Inst 98:610-619, 2006.
23. Neugut AI, Matasar M, Wang X, et al: Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 24:2368-2375, 2006.
24. Keating NL, Landrum MB, Klabunde CN, et al: Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26:2532-2537, 2008.
25. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091, 2006.
26. Popescu RA, Norman A, Ross PJ, et al: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412-2418, 1999.
27. Zalcberg J, Kerr D, Seymour L, et al: Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 34:1871-1875, 1998.
28. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004.
29. Ramsey SD, Andersen MR, Etzioni R, et al: Quality of life in survivors of colorectal carcinoma. Cancer 88:1294-1303, 2000.
30. Muss HB, Cohen HJ, Lichtman SM: Clinical research in the older cancer patient. Hematol Oncol Clin North Am 14:283-291, 2000.
31. Yellen SB, Celia DF, Leslie WT: Age and clinical decision making in oncology patients. J Natl Cancer Inst 86:1766-1770, 1994.
32. Newcomb PA, Carbone PP: Cancer treatment and age: Patient perspectives. J Natl Cancer Inst 85:1580-1584, 1993.
33. Yancik R, Wesley MN, Ries LA, et al: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study. Cancer 82:2123-2134, 1998.
34. Zafar Y, Provenzale D, Herndon JEII, et al: The impact of comorbidity on diagnosis and treatment of colorectal cancer (CRC) (abstract 261). Proceedings of the 2007 Gastrointestinal Cancers Symposium. Orlando, Fla; Jan 19-21, 2007.
35. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587, 1998.
36. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007.
37. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, et al: Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 43:2161-2169, 2007.
38. Hurria A, Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 104:1998-2005, 2005.
39. Rodin MB, Mohile SG: A practical approach to geriatric assessment in oncology. J Clin Oncol 25:1936-1944, 2007.
40. Repetto L, Fratino L, Audisio RA, et al: Comprehensive geriatric assessment adds informarion to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology study. J Clin Oncol 20:494-502, 2002.
41. Gross CP, McAvay GJ, Krumholz HM, et al: The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: Implications for screening. Ann Intern Med 145:646-653, 2006.
42. Sargent DJ, Wieand HS, Hailer DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005,
43. Kelly H, Goldberg RM: Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 23:4553-4560, 2005.
44. Sanoff HK, Bleiberg H, Goldberg RM: Managing older patients with colorectal cancer. J Clin Oncol 25:1891-1897, 2007.
45. Hailer DG, Catalano PJ, Macdonald JS, et al: Phase 111 study of fluorouracil, leucovorin, and levamisole in high-risk stage II and HI colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005.
46. Andre T, Colin P, Louvet C, et al: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage H and HI colon cancer: Results of a randomized trial. J Clin Oncol 21:2896-2903, 2003.
47. Chau I, Norman AR, Cunningham D, et al: A randomised comparison between 6 months of bolus fluorouracil/leucovodn and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16:549-557, 2005.
48. Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage HI colon cancer. N Engl J Med 352:2696-2704, 2005.
49. de Gramont A, Boni C, Navarro M, et al: Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years (abstract 4007). J Clin Oncol 25(18S):165s, 2007.
50. Cassidy J, Tabernero J, Twelves C, et al: XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084-2091, 2004.
51. Comella P, Natale D, Farris A, et al: Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 104:282-289, 2005.
52. Schmoll HI, Cartwright T, Tabernero J, et al: Phase HI trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. J Clin Oncol 25:102-109, 2007.
53. Scappaticci FA, Skillings JR, Holden SN, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239, 2007.
54. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorourucil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004.
55. Schrag D, Rifas-Shiman S, Saltz L, et al: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999-4005, 2002.